A61K 38/15
Depsipeptides
Official title: Depsipeptides; Derivatives thereof
A61K38/15 (Depsipeptides) appears on 195 US grants and 407 published applications in this corpus.
Search patents in A61K- Granted patents
- 195
- Published applications
- 407
- Assignees
- 194
- Inventors
- 780
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 3 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 1 |
| 2003 | 1 | 6 |
| 2004 | 1 | 11 |
| 2005 | 0 | 11 |
| 2006 | 0 | 14 |
| 2007 | 2 | 6 |
| 2008 | 2 | 6 |
| 2009 | 2 | 12 |
| 2010 | 3 | 9 |
| 2011 | 6 | 24 |
| 2012 | 1 | 8 |
| 2013 | 6 | 16 |
| 2014 | 12 | 19 |
| 2015 | 14 | 27 |
| 2016 | 11 | 19 |
| 2017 | 8 | 28 |
| 2018 | 13 | 25 |
| 2019 | 21 | 23 |
| 2020 | 15 | 26 |
| 2021 | 18 | 26 |
| 2022 | 10 | 21 |
| 2023 | 12 | 22 |
| 2024 | 12 | 16 |
| 2025 | 11 | 21 |
| 2026 | 9 | 10 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Histone deacetylase inhibitors for use in immunotherapy22 Sep 2026US 12,740,986 B2Viracta Subsidiary, Inc.
- Delivery of cyclic compound by using carrier25 Aug 2026US 12,714,754 B2The University of Tokyo
- Pharmaceutical compositions comprising teixobactin14 Jul 2026US 12,678,479 B2NovoBiotic Pharmaceuticals, LLC
- PLD for use in combination in the treatment of coronavirus9 Jun 2026US 12,648,986 B2Pharma Mar, S. A.
- Compounds for use in viral infections19 May 2026US 12,630,589 B2Pharma Mar, S. A.
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Hdac inhibitors for use with nk cell based therapies24 Sep 2026US 2026/0284060 A9NantKwest, Inc.
- Histone deacetylase inhibitors for use in immunotherapy24 Sep 2026US 2026/0284061 A9Viracta Subsidiary, Inc.
- Combination of roginolisib and hdac inhibitor in the treatment of haematological malignancy20 Aug 2026US 2026/0240863 A1iOnctura SA
- Pharmaceutical composition and use thereof2 Jul 2026US 2026/0183300 A1Tsinghua University
Most cited
By later US patents
- Therapeutic combinations comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid32US 7,968,565 B2Sunesis Pharmaceuticals, Inc. · 2011
- Methods for therapy of radiation cutaneous syndrome30US 6,809,118 B22004
- Anti-biofilm compositions and methods for using28US 8,741,855 B2Board of Trustees of the University of Arkansas · 2014
- Dehydrodidemnin B as an L-type calcium channel enhancer21US 6,030,943 A2000
- Endoparasiticidal compositions21US 6,159,932 ABayer Aktiengesellschaft · 2000